#BEGIN_DRUGCARD DB02942

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
18225

# Chemical_Formula:
C6H14O12P2

# Chemical_IUPAC_Name:
{[(1R,2S,3s,4R,5S,6r)-2,3,4,6-tetrahydroxy-5-(phosphonooxy)cyclohexyl]oxy}phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Inositol 1,3-Bisphosphate

# HET_ID:
ITP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H14O12P2/c7-1-2(8)5(17-19(11,12)13)4(10)6(3(1)9)18-20(14,15)16/h1-10H,(H2,11,12,13)(H2,14,15,16)/t1-,2-,3+,4-,5+,6-

# InChI_Key:
InChIKey=PUVHMWJJTITUGO-KNBDEEDGSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2942

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
340.1157

# Molecular_Weight_Mono:
339.996048936

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1HYI

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.3

# Predicted_LogS:
-1.1

# Predicted_Water_Solubility:
2.39e+01 g/l

# Primary_Accession_No:
DB02942

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
128419

# PubChem_Substance_ID:
46506084

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01941

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[C@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:41 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm. Endosome
early endosomal membrane
early endosome
peripheral membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
EEA1

# Drug_Target_1_GenBank_ID_Gene:
L40157

# Drug_Target_1_GenBank_ID_Protein:
1016368

# Drug_Target_1_GeneCard_ID:
EEA1

# Drug_Target_1_Gene_Name:
EEA1

# Drug_Target_1_Gene_Sequence:
>4233 bp
ATGTTAAGGAGGATTTTACAGAGGACTCCTGGGAGAGTTGGCTCTCAAGGTTCTGATTTA
GATTCATCAGCAACTCCTATAAACACAGTGGACGTCAATAATGAAAGCTCTTCAGAAGGT
TTCATATGTCCCCAGTGTATGAAATCTCTTGGATCTGCTGATGAACTTTTCAAACATTAT
GAAGCTGTTCATGATGCTGGTAATGACTCAGGTCATGGAGGAGAGTCTAATCTTGCTTTG
AAGCGAGATGATGTAACACTGCTCAGACAAGAGGTCCAAGACCTACAGGCTTCACTTAAG
GAAGAAAAATGGTACTCGGAAGAATTAAAGAAGGAATTAGAAAAATATCAAGGGCTGCAG
CAGCAAGAGGCCAAACCTGATGGGTTGGTGACTGATTCATCAGCAGAACTACAGTCTTTG
GAACAGCAATTAGAAGAAGCCCAAACAGAAAATTTTAATATTAAGCAAATGAAAGACTTA
TTTGAACAGAAAGCAGCCCAACTTGCTACTGAAATTGCAGATATAAAGTCAAAGTATGAT
GAAGAAAGGAGTCTTCGAGAAGCTGCTGAACAAAAAGTGACACGTCTGACAGAAGAATTA
AACAAAGAGGCAACTGTAATTCAAGATCTGAAGACGGAACTGCTTCAGAGACCTGGTATA
GAAGATGTTGCCGTGCTAAAGAAAGAACTGGTCCAAGTTCAAACACTAATGGATAACATG
ACCTTGGAACGTGAGCGAGAATCTGAAAAACTCAAAGATGAATCGAAAAAATTCGAGTCA
CAATATGCTAGCTCAGAGGCCACAATAAGCCAGCTAAGGAGTGAACTGTCCAAAGGCCCC
CAGGAAGTTCGTGTATATGTACAGGAACTACAAAAACTGAAAAGTTCAGTTAATGAATTA
ACACAAAAAAATCAGACCTTGACAGAAAACTTGCTGAAAAAAGAACAAGACTATACTAAG
TTAGAGGAGAAACATAATGAAGAATCTGTGAGTAAAAAGAATATTCAGGCAACCCTTCAT
CAAAAAGACCTAGATTGTCAACAGCTTCAGTCAAGATTGTCTGCATCTGAAACCTCACTG
CATAGAATACATGTAGAACTAAGTGAAAAAGGAGAAGCTACTCAAAAGCTCAAAGAAGAA
TTATCTGAGGTAGAGACCAAGTACCAGCATCTAAAGGCGGAGTTTAAGCAGCTACAACAA
CAGAGAGAAGAAAAGGAGCAGCATGGGTTACAACTCCAAAGTGAAATTAATCAATTACAT
AGCAAACTTCTGGAGACAGAGCGCCAACTAGGGGAAGCTCATGGTAGGCTGAAGGAACAG
AGACAGCTTTCAAGTGAAAAGTTGATGGATAAAGAACAACAAGTGGCTGATTTACAACTC
AAACTTTCTCGGTTAGAAGAGCAGTTGAAGGAAAAAGTTACAAATTCTACAGAATTGCAG
CATCAATTAGATAAAACAAAGCAACAGCATCAAGAACAACAGGCTCTTCAGCAAAGCACC
ACGGCAAAACTTCGAGAAGCTCAGAATGATTTGGAACAAGTTCTACGTCAAATTGGCGAA
AAGGACCAAAAGATCCAGAACCTTGAAGCTTTATTACAGAAGAGTAAAGAAAATATTTCA
TTACTAGAAAAAGAAAGAGAAGATCTTTATGCAAAAATTCAGGCTGGTGAAGGAGAGACT
GCTGTTCTTAACCAGTTACAAGAAAAAAACCATACACTACAGGACGAAGTAACTCAACTA
ACAGAGAACGTGAAGAATCAGTCAGAAAGTCATAAACAAGCCCAGGAGAATTTGCATGAC
CAGGTACAAGAGCAGAAGGCACATCTTAGAGCTGCACAAGACCGTGTCCTTTCCCTAGAA
ACTAGTGTCAATGAATTAAATAGTCAATTAAATGAAAGCAAGGAGAAGGTCTCCCAGCTT
GACATACAGATTAAAGCCAAAACCGAACTATTACTATCAGCAGAAGCAGCAAAAACTGCT
CAAAGAGCTGATCTTCAGAATCATTTGGACACAGCTCAAAATGCATTACAAGATAAACAC
CAGGAGTTAAATAAGATTACTACTCAGTTGGATCAGGTCACTGCAAAGTTACAAGACAAG
CAAGAACATTGCAGTCAGCTGGAAAGTCATCTTAAAGAATATAAAGAGAAATACCTCTCT
TTAGAACAGAAAACCGAAGAGCTAGAAGGTCAAATTAAGAAACTAGAAGCTGATAGTCTT
GAAGTTAAAGCAAGCAAGGAGCAGGCTTTGCAAGATCTACAACAGCAAAGACAGCTGAAC
ACAGATTTAGAGCTCAGAGCCACAGAATTGAGTAAACAACTTGAAATGGAGAAGGAAATA
GTATCCAGTACAAGATTGGATCTACAGAAAAAATCTGAAGCCCTTGAAAGTATCAAGCAA
AAGCTTACCAAGCAAGAGGAAGAAAAACAAATCCTGAAACAAGATTTTGAAACTTTAAGT
CAAGAAACAAAGATTCAGCATGAGGAATTGAATAACAGAATTCAAACAACAGTAACAGAA
CTACAAAAAGTGAAAATGGAGAAAGAAGCTTTAATGACAGAGCTTTCTACAGTAAAGGAC
AAACTATCAAAAGTTTCTGATTCTTTGAAAAACTCTAAAAGTGAATTTGAAAAGGAGAAT
CAGAAAGGAAAAGCCGCTATATTAGACTTGGAAAAAACTTGCAAAGAATTAAAGCATCAA
CTTCAAGTGCAGATGGAAAACACACTTAAGGAACAGAAGGAACTGAAAAAGTCACTTGAA
AAAGAGAAGGAGGCTTCTCATCAGTTGAAATTGGAACTCAATTCAATGCAGGAACAACTT
ATACAGGCCCAGAATACTTTAAAACAAAATGAAAAAGAAGAGCAACAACTTCAGGGGAAC
ATAAATGAGCTAAAGCAATCAAGTGAACAGAAGAAAAAACAAATTGAAGCACTCCAAGGA
GAGCTTAAAATTGCTGTTTTACAGAAGACAGAGCTTGAGAATAAACTACAGCAGCAGTTA
ACACAGGCAGCCCAGGAACTTGCAGCAGAGAAAGAGAAAATATCAGTATTACAAAACAAC
TATGAAAAAAGTCAGGAAACTTTCAAACAGCTTCAATCTGATTTCTATGGGAGGGAATCT
GAACTTCTAGCCACCAGGCAAGATCTTAAGTCTGTAGAAGAGAAGCTTTCTCTAGCACAG
GAGGACTTGATTTCAAACAGAAATCAAATTGGAAATCAAAATAAATTGATTCAAGAACTG
AAGACTGCCAAGGCTACATTGGAGCAGGATTCAGCAAAGAAAGAACAGCAATTGCAGGAG
CGATGTAAAGCACTACAAGACATTCAGAAAGAAAAGTCACTGAAAGAAAAAGAACTGGTA
AATGAGAAGTCTAAATTGGCAGAGATAGAAGAAATTAAATGTAGACAAGAAAAAGAAATC
ACTAAACTAAACGAAGAACTCAAGTCCCACAAACTAGAAAGCATAAAGGAGATAACAAAT
CTTAAAGATGCTAAACAGCTTCTAATTCAGCAGAAATTAGAACTTCAAGGAAAAGCGGAC
TCCCTGAAGGCAGCTGTTGAACAGGAGAAGAGAAATCAGCAGATACTAAAAGACCAGGTG
AAAAAGGAAGAAGAGGAGCTGAAGAAAGAATTTATTGAGAAAGAAGCTAAGTTGCATTCC
GAAATAAAAGAAAAGGAAGTAGGAATGAAGAAGCATGAAGAAAATGAGGCTAAACTTACC
ATGCAGATTACAGCATTAAATGAAAACTTAGGCACTGTGAAGAAGGAGTGGCAATCTAGT
CAACGGAGAGTTAGTGAGCTTGAGAAACAAACGGATGACTTACGGGGTGAAATTGCAGTA
TTAGAAGCAACGGTTCAGAATAATCAAGATGAAAGGAGAGCACTACTGGAAAGATGTCTT
AAAGGAGAAGGTGAAATAGAAAAGCTTCAAACCAAAGTATTAGAATTGCAAAGAAAGCTG
GATAATACAACTGCAGTGCAGGAGCTGGGCAGAGAAAACCAATCACTTCAGATCAAACAT
ACACAAGCGTTGAATAGAAAGTGGGCCGAAGACAATGAAGTACAAAACTGTATGGCCTGT
GGGAAAGGCTTTTCAGTAACAGTGAGACGGCATCACTGCCGACAGTGTGGAAATATCTTC
TGTGCTGAATGTTCAGCCAAAAATGCCTTAACTCCTTCCTCCAAGAAGCCTGTTCGTGTC
TGTGATGCATGTTTCAATGACTTGCAAGGATAA

# Drug_Target_1_General_Function:
Cell cycle control, cell division, chromosome partitioning

# Drug_Target_1_General_References:
10394369	Kutateladze TG, Ogburn KD, Watson WT, de Beer T, Emr SD, Burd CG, Overduin M: Phosphatidylinositol 3-phosphate recognition by the FYVE domain. Mol Cell. 1999 Jun;3(6):805-11.
10491193	Callaghan J, Nixon S, Bucci C, Toh BH, Stenmark H: Direct interaction of EEA1 with Rab5b. Eur J Biochem. 1999 Oct 1;265(1):361-6.
10506127	Simonsen A, Gaullier JM, D'Arrigo A, Stenmark H: The Rab5 effector EEA1 interacts directly with syntaxin-6. J Biol Chem. 1999 Oct 8;274(41):28857-60.
10807926	Gaullier JM, Ronning E, Gillooly DJ, Stenmark H: Interaction of the EEA1 FYVE finger with phosphatidylinositol 3-phosphate and early endosomes. Role of conserved residues. J Biol Chem. 2000 Aug 11;275(32):24595-600.
11230696	Kutateladze T, Overduin M: Structural mechanism of endosome docking by the FYVE domain. Science. 2001 Mar 2;291(5509):1793-6.
11741531	Dumas JJ, Merithew E, Sudharshan E, Rajamani D, Hayes S, Lawe D, Corvera S, Lambright DG: Multivalent endosome targeting by homodimeric EEA1. Mol Cell. 2001 Nov;8(5):947-58.
11870209	Kauppi M, Simonsen A, Bremnes B, Vieira A, Callaghan J, Stenmark H, Olkkonen VM: The small GTPase Rab22 interacts with EEA1 and controls endosomal membrane trafficking. J Cell Sci. 2002 Mar 1;115(Pt 5):899-911.
12493736	Merithew E, Stone C, Eathiraj S, Lambright DG: Determinants of Rab5 interaction with the N terminus of early endosome antigen 1. J Biol Chem. 2003 Mar 7;278(10):8494-500. Epub 2002 Dec 19.
7768953	Mu FT, Callaghan JM, Steele-Mortimer O, Stenmark H, Parton RG, Campbell PL, McCluskey J, Yeo JP, Tock EP, Toh BH: EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. J Biol Chem. 1995 Jun 2;270(22):13503-11.
9697774	Simonsen A, Lippe R, Christoforidis S, Gaullier JM, Brech A, Callaghan J, Toh BH, Murphy C, Zerial M, Stenmark H: EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. Nature. 1998 Jul 30;394(6692):494-8.

# Drug_Target_1_HGNC_ID:
HGNC:3185

# Drug_Target_1_HPRD_ID:
05460

# Drug_Target_1_ID:
3303

# Drug_Target_1_Locus:
12q22

# Drug_Target_1_Molecular_Weight:
162468

# Drug_Target_1_Name:
Early endosome antigen 1

# Drug_Target_1_Number_of_Residues:
1411

# Drug_Target_1_PDB_ID:
1JOC

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01363	FYVE

# Drug_Target_1_Protein_Sequence:
>Early endosome antigen 1
MLRRILQRTPGRVGSQGSDLDSSATPINTVDVNNESSSEGFICPQCMKSLGSADELFKHY
EAVHDAGNDSGHGGESNLALKRDDVTLLRQEVQDLQASLKEEKWYSEELKKELEKYQGLQ
QQEAKPDGLVTDSSAELQSLEQQLEEAQTENFNIKQMKDLFEQKAAQLATEIADIKSKYD
EERSLREAAEQKVTRLTEELNKEATVIQDLKTELLQRPGIEDVAVLKKELVQVQTLMDNM
TLERERESEKLKDECKKLQSQYASSEATISQLRSELAKGPQEVAVYVQELQKLKSSVNEL
TQKNQTLTENLLKKEQDYTKLEEKHNEESVSKKNIQATLHQKDLDCQQLQSRLSASETSL
HRIHVELSEKGEATQKLKEELSEVETKYQHLKAEFKQLQQQREEKEQHGLQLQSEINQLH
SKLLETERQLGEAHGRLKEQRQLSSEKLMDKEQQVADLQLKLSRLEEQLKEKVTNSTELQ
HQLDKTKQQHQEQQALQQSTTAKLREAQNDLEQVLRQIGDKDQKIQNLEALLQKSKENIS
LLEKEREDLYAKIQAGEGETAVLNQLQEKNHTLQEQVTQLTEKLKNQSESHKQAQENLHD
QVQEQKAHLRAAQDRVLSLETSVNELNSQLNESKEKVSQLDIQIKAKTELLLSAEAAKTA
QRADLQNHLDTAQNALQDKQQELNKITTQLDQVTAKLQDKQEHCSQLESHLKEYKEKYLS
LEQKTEELEGQIKKLEADSLEVKASKEQALQDLQQQRQLNTDLELRATELSKQLEMEKEI
VSSTRLDLQKKSEALESIKQKLTKQEEEKQILKQDFETLSQETKIQHEELNNRIQTTVTE
LQKVKMEKEALMTELSTVKDKLSKVSDSLKNSKSEFEKENQKGKAAILDLEKTCKELKHQ
LQVQMENTLKEQKELKKSLEKEKEASHQLKLELNSMQEQLIQAQNTLKQNEKEEQQLQGN
INELKQSSEQKKKQIEALQGELKIAVLQKTELENKLQQQLTQAAQELAAEKEKISVLQNN
YEKSQETFKQLQSDFYGRESELLATRQDLKSVEEKLSLAQEDLISNRNQIGNQNKLIQEL
KTAKATLEQDSAKKEQQLQERCKALQDIQKEKSLKEKELVNEKSKLAEIEEIKCRQEKEI
TKLNEELKSHKLESIKEITNLKDAKQLLIQQKLELQGKADSLKAAVEQEKRNQQILKDQV
KKEEEELKKEFIEKEAKLHSEIKEKEVGMKKHEENEAKLTMQITALNENLGTVKKEWQSS
QRRVSELEKQTDDLRGEIAVLEATVQNNQDERRALLERCLKGEGEIEKLQTKVLELQRKL
DNTTAAVQELGRENQSLQIKHTQALNRKWAEDNEVQNCMACGKGFSVTVRRHHCRQCGNI
FCAECSAKNALTPSSKKPVRVCDACFNDLQG

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Binds phospholipid vesicles containing phosphatidylinositol 3-phosphate and participates in endosomal trafficking

# Drug_Target_1_SwissProt_ID:
Q15075

# Drug_Target_1_SwissProt_Name:
EEA1_HUMAN

# Drug_Target_1_Synonyms:
Endosome-associated protein p162
Zinc finger FYVE domain-containing protein 2

# Drug_Target_1_Theoretical_pI:
5.38

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB02942
